SCHEMBL746154

SCHEMBL746154

CN1C(=O)Cc2cc(Br)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.57
BMPR1B O00238 5/20 0.49
BMPR1A P36894 5/20 0.49
ACVRL1 P37023 5/20 0.49
ACVR1 Q04771 5/20 0.49
TRIM24 O15164 2/20 0.49
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
TGFBR1 P36897 2/20 0.46
PKM P14618 2/20 0.46
CASP2 P42575 1/20 0.46
SRD5A1 P18405 1/20 0.45
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL290257 0.85 IDO1 (0.47) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL30683070 0.85 IDO1 (0.47) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL31711759 0.84 BRD4 (0.44) IDO1CASP2SRD5A1GABRA1GABRG2
SCHEMBL265640 0.84 SRD5A1 (0.59) IDO1TRIM24CASP2SRD5A1GABRA1
SCHEMBL19224681 0.81 BMPR1B (0.49) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL30832131 0.81 BMPR1B (0.49) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL21173084 0.80 SRD5A1 (0.48) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL30222138 0.79 TRIM24 (0.54) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL434054 0.79 TRIM24 (0.54) IDO1BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL22667347 0.78 BMPR1B (0.51) IDO1BMPR1BBMPR1AACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 US disclosed
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-04-23 US disclosed
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-03-19 US disclosed
EP-4344702-B1 PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2026-01-28 EP disclosed
EP-4605395-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Dong-A ST Co., Ltd. (KR) 2025-08-27 EP disclosed
CN-119384413-A Anilino-pyrazole derivatives, compositions and methods thereof 昂胜医药有限公司 2025-01-28 CN disclosed
CN-118878450-A C3-trifluoropropionyl oxydation reaction of N-substituted indole 湖南科技职业学院 2024-11-01 CN disclosed
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof Ensem Therapeutics (US) 2024-07-25 US disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 EP disclosed
CN-115636778-B Synthesis method of 3-quaternary carbon substituted indoline-2-ketone compound 常州大学 2024-05-07 CN disclosed
WO-2010130794-A1 5-PYRIDIN-3-YL-1,3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 NOVARTIS AG (CH) 2010-11-18 WO disclosed
US-6228868-B1 ANTICARCINOGENIC AND ANTITUMOR AGENTS ABBOTT LABORATORIES 2001-05-08 US disclosed
US-6133305-A PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER SUGEN, INC. (US) 2000-10-17 US disclosed
WO-2000006556-A1 SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS ABBOTT LABORATORIES (US) 2000-02-10 WO disclosed
EP-0623614-B1 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors ZENECA LTD (GB) 1998-02-25 EP disclosed
CN-1121715-A 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors ZENECA LTD (GB) 1996-05-01 CN disclosed
US-5512594-A ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES ZENECA LIMITED (GB) 1996-04-30 US disclosed
US-5478842-A Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes ZENECA LIMITED (GB) 1995-12-26 US disclosed
WO-1994025453-A1 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS ZENECA LIMITED (GB) 1994-11-10 WO disclosed
EP-0623614-A1 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors ZENECA LIMITED (GB) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 IDO1 37/4885BMPR1B 2082/4885BMPR1A 1293/4885
US-20240246950-A1 Anilino-Pyrazole Derivatives, Compositions and Methods Thereof CDK2, CDK3, CDK4 IDO1 1475/4885BMPR1B 3158/4885BMPR1A 3179/4885
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, MCL1 IDO1 4515/4885BMPR1B 2278/4885BMPR1A 2494/4885
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS KRAS, MYC, NRAS IDO1 3947/4885BMPR1B 2304/4885BMPR1A 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.